J Gynecol Oncol.  2014 Apr;25(2):155-155. 10.3802/jgo.2014.25.2.155.

Consideration of EphA2 in relation to epithelial-mesenchymal transition in uterine endometrial cancer

  • 1Department of Obstetrics and Gynecology, Dongguk University School of Medicine, Gyeongju, Korea. hwangmd@dongguk.ac.kr


No abstract available.

MeSH Terms

Endometrial Neoplasms*
Epithelial-Mesenchymal Transition*


1. Yang WN, Ai ZH, Wang J, Xu YL, Teng YC. Correlation between the overexpression of epidermal growth factor receptor and mesenchymal makers in endometrial carcinoma. J Gynecol Oncol. 2014; 25:36–42.
2. Merritt WM, Kamat AA, Hwang JY, Bottsford-Miller J, Lu C, Lin YG, et al. Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer. Cancer Biol Ther. 2010; 10:1306–1314.
3. Huang J, Xiao D, Li G, Ma J, Chen P, Yuan W, et al. EphA2 promotes epithelial-mesenchymal transition through the Wnt/β-catenin pathway in gastric cancer cells. Oncogene. 2013; 06. 10. [Epub]. http://dx.doi.org/10.1038/onc.2013.238.
4. Giannoni E, Taddei ML, Parri M, Bianchini F, Santosuosso M, Grifantini R, et al. EphA2-mediated mesenchymal-amoeboid transition induced by endothelial progenitor cells enhances metastatic spread due to cancer-associated fibroblasts. J Mol Med (Berl). 2013; 91:103–115.
Full Text Links
  • JGO
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr